Company news

Imugene Ltd news in 2024

Imugene Ltd's news releases, calls and decks from 2024, newest first.

View company

Issuance of Convertible Notes & Warrants for up to $46m

December 23, 2024

Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund

December 18, 2024

onCARlytics Trial Doses First Patient in IT Combination Arm

November 10, 2024

Imugene Opens First Australian Site for azer-cel Trial

November 7, 2024

Complete Response in MAST Study Maintained Over Two Years

November 4, 2024

Imugene Receives Orphan Drug Designation for VAXINIA

September 18, 2024

Three Complete Responses in Azer-Cel Phase 1b Trial

September 1, 2024

First patient dosed in Phase 1 bile tract cancer trial

July 9, 2024

Imugene onCARlytics Doses First Patient in IV Combination

June 23, 2024

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million

April 16, 2024

Imugene and Kincell Bio Announce Strategic Partnership

April 15, 2024

Bile Tract Cancer Study Opens after MAST High Dose Clearance

April 14, 2024

VAXINIA and HER-Vaxx featured at the AACR Annual Meeting

April 7, 2024

Oncolytic Virotherapy CF33 Patent Granted in China

April 3, 2024

Imugene to present at 2024 Cholangiocarcinoma Conference

April 2, 2024

Phase 1 onCARlytics Trial Advances to Combination Arm

March 10, 2024

Phase 1 onCARlytics Trial Doses First Intravenous Patient

February 14, 2024

VAXINIA Phase 1 trial doses patients in higher dose cohorts

January 18, 2024

Phase 1 CF33-hNIS Study Update - Positive Early Signals

January 16, 2024

Decks in 2024